The World Health Organization (WHO) on Thursday endorsed the use of Pfizer Inc's oral COVID-19 antiviral treatment in high-risk patients after an analysis of trial data by the U.N. agency showed the therapy dramatically cut the risk of hospitalisation.
The recommendation comes as thousands of people die of COVID-19 every week, despite a waning global infection rate. Of existing COVID-19 treatments, Pfizer's PFE.N Paxlovid is by far the most potent, the WHO said.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
